A5044046113- Multiple Sclerosis Research Studies
- Chronic Lymphocytic Leukemia Research
- Polyomavirus and related diseases
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Neuroendocrine Tumor Research Advances
- Peripheral Neuropathies and Disorders
- Fungal Plant Pathogen Control
- Autoimmune and Inflammatory Disorders Research
- SARS-CoV-2 and COVID-19 Research
- Rheumatoid Arthritis Research and Therapies
- Medical and Biological Sciences
- Systemic Sclerosis and Related Diseases
- Mycobacterium research and diagnosis
- Neurogenesis and neuroplasticity mechanisms
- Genetic Neurodegenerative Diseases
- Healthcare innovation and challenges
- Powdery Mildew Fungal Diseases
- Long-Term Effects of COVID-19
- Health Systems, Economic Evaluations, Quality of Life
- Mental Health and Patient Involvement
- Chronic Disease Management Strategies
- Healthcare Systems and Challenges
- Cerebral Palsy and Movement Disorders
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
Royal London Hospital
2018-2024
Queen Mary University of London
2021-2024
Barts Health NHS Trust
2016-2024
Hospital de Egas Moniz
2023
St George's, University of London
2016
Technological innovation is transforming traditional clinical practice, enabling people with multiple sclerosis (pwMS) to contribute healthcare outcome data remotely between clinic visits. In both relapsing and progressive forms of (MS), patients may experience variable disability accrual symptoms throughout their disease course. The potential impact on the quality life (QoL) in pwMS families carers profound. introduction treatment targets, such as NEDA (no evidence activity) NEPAD...
Cladribine is an effective immunotherapy for people with multiple sclerosis (pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two treatment courses), disease activity re-emerges in others. The characteristics of developing re-emerging remain incompletely understood.To explore whether clinical and/or paraclinical baseline characteristics, including the degree lymphocyte reduction, drug dose and lesions on magnetic resonance imaging (MRI) are associated...
<h3>Background</h3> Evidence suggests Cladribine is a highly effective, safe and convenient disease modifying treatment (DMT) for people with multiple sclerosis (pwMS). We report our experience using in pwMS. <h3>Methods</h3> was offered to pwMS clinical and/or MRI activity, however restricted choice of DMT. Treatment cycles consisted administered as subcutaneous injections over total up 6 days (10 mg/day) 5 weeks, adjusted individual lymphocyte counts. <h3>Results</h3> Seventeen (ten women...
To evaluate the association between social capital (SC) and physical psychological impact of multiple sclerosis (MS).A cross-sectional study was conducted among people with MS (pwMS) at The Royal London Hospital, London, UK. Participants completed a survey including Multiple Sclerosis Impact Scale-29 (MSIS-29), Hospital Anxiety Depression Scale (HADS), self-reported EDSS SC questionnaire (SCQ). SCQ assessed personal relationships, support networks, civic engagement, trust cooperative norms....
To report on safety and effectiveness of subcutaneous cladribine (Litak®) in multiple sclerosis (MS) patients.Litak® was offered to MS-patients irrespective disease course. Litak® 10 mg administered for 3-4 days during week 1. Based lymphocyte count at 4, patients received another 0-3 doses 5. A second course 11 months later. Follow-up included adverse events, relapses, expanded disability status scale (EDSS), 9-hole-peg Timed-25-foot-walking tests, no-evidence-of-disease-activity (NEDA),...
Cladribine is a deoxyadenosine analogue that can penetrate the blood-brain barrier. It used to treat multiple sclerosis (MS). However, mechanistic understanding of effect this highly effective therapy on B cells and plasma in central nervous system compartment limited. The CLADRIPLAS study examined cladribine peripheral intrathecal cell biology people with MS. Thirty-eight progressive MS ineligible for- or rejecting-treatment licenced therapies were recruited supplied baseline lumbar...
Parakinesia brachialis oscitans (PBO) is the involuntary movement of an otherwise paretic upper limb triggered by yawning. We describe first case PBO in a patient with manifestation tumefactive multiple sclerosis (MS).A 35-year-old man presented to emergency department episode generalized seizure. Neurologic examination revealed left-sided spastic hemiparesis, predominantly affecting his limb. Brain MRI showed right hemisphere lesion consistent demyelination. CSF did not document unmatched...
ABSTRACT Background Cladribine is a deoxyadenosine analogue that can penetrate the blood-brain barrier. It used to treat multiple sclerosis. However, mechanistic understanding of effect this highly effective therapy on B cells and plasma in central nervous system compartment limited. Objectives The CLADRIPLAS study examined cladribine peripheral intrathecal cell biology people with MS. Methods Thirty-eight progressive MS ineligible for- or rejecting-treatment licenced therapies were...
<h3>Background</h3> Evidence suggests cladribine is an effective, safe and convenient disease modifying therapy (DMT) for people with multiple sclerosis (pwMS). <h3>Objective</h3> To report our clinical experience using in pwMS a dosing scheme adapted to individual total lymphocyte count (TLC) thereby addressing key safety concern raised the rejection of oral by European Medicines Agency 2011. <h3>Methods</h3> Subcutaneous 10 mg/day was administered on up seven days five weeks who had and/or...
To address a critical issue - severe treatment-induced lymphopenia during the European Medicines Agency (EMA)-assessment of cladribine, highly effective disease modifying treatment (DMT) for people with multiple sclerosis (pwMS).
Objectives Increase people with MS (PwMS) engagement research and provide increased utility to PwMS/Clinicians. Background The UK Register (UKMSR) was established by the Society collect service provision data. We have now collected 8 years of Patient Reported Outcome (PRO) data from PwMS, more than 300,000 responses, thus far little feedback given participants. Methods report our first experience providing Public Involvement (PPI) utilised better design collection instruments. Gathered...
Objective To examine the association between socioeconomic status (SES) and prescription of disease-modifying treatments (DMTs) in people with multiple sclerosis (pwMS). Methods A cross-sectional study was conducted among 734 pwMS aged ≥18 years attending neuroinflammation service at The Royal London Hospital (Barts Health NHS Trust) 1997 2017. SES determined by patient income education extracted from English Index Multiple Deprivation. Multinomial logistic regression performed to assess...
Abstract Background Cognitive problems affect up to 70% of people with multiple sclerosis (MS), which can negatively impact mood, ability work, and quality life. Addressing cognitive is a top 10 research priority for MS. Our ongoing has systematically developed screening management pathway (NEuRoMS) tailored MS, involving brief evaluation rehabilitation intervention. The present study aims assess the feasibility delivering will inform design definitive randomised controlled trial (RCT)...